drugset / Trial / NCT02913430
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
RandomizedParallel-groupOpen-labelTreatment
Summary
To assess longitudinal changes in allele frequency of ESR1 mutation in plasma in patients treated with Fulvestrant plus palbociclib compared to tamoxifen plus palbociclib
Timeline
- Start
- 2018-04-24
- Primary completion
- 2022-04-12
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Comparator | Tamoxifen | Small molecule | 20 mg | Oral |
| Comparator | Palbociclib | Small molecule | 125 mg | Oral |